Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader with immunomodulatory drug (IMiD) activity for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader without IMiD activity for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; DeTIL-0255 for tumor infiltrating lymphocytes therapy; KINASE-CTM3 to treat T cell malignancies and autoimmune diseases; and LIGASE-INH2 for immuno-oncology. In addition, the company develops programs, such as COVID-CTM1, COVID-CTM2, and COVID-CTM3 that are designed for protein degradation to SARs CoV2 targets. Nurix Therapeutics, Inc. has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.
IPO Year: 2020
Exchange: NASDAQ
Website: nurixtx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/17/2025 | $16.00 | Market Perform | Leerink Partners |
| 12/10/2024 | $35.00 | Buy | BTIG Research |
| 12/6/2024 | $35.00 | Outperform | BMO Capital Markets |
| 10/24/2024 | $35.00 | Buy | UBS |
| 10/11/2024 | $41.00 | Buy | Jefferies |
| 9/6/2024 | $26.00 | Outperform | Robert W. Baird |
| 7/31/2024 | $36.00 | Buy | Truist |
| 6/26/2023 | $25.00 | Outperform | Oppenheimer |
| 3/9/2023 | $20.00 | Overweight | Barclays |
| 2/28/2023 | $25.00 | Outperform | Oppenheimer |
SAN FRANCISCO, May 16, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases, today announced that on May 13, 2025, the company granted inducement awards to thirteen new employees. The grants were made pursuant to Nurix's 2024 Equity Inducement Plan as an inducement material to the employees' acceptance of employment with Nurix and were approved by the Compensation Committee of Nurix's Board of Directors i
SAN FRANCISCO, May 15, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Hans van Houte, chief financial officer of Nurix, and Jason Kantor, Ph.D., chief business officer of Nurix, will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 21, 2025, at 2:05 p.m. ET. The conference is being held in New York, NY. The fireside chat will be webcast live and can be accessed via a link in the Investors section of the Nurix website. The archived webcast will be avail
Nurix's DEL-AI platform uses a first-in-class DEL Foundation Model trained on the Company's proprietary DNA encoded library data Nurix's DEL Foundation Model can accurately predict novel binders to therapeutically relevant targets, including many targets considered undruggable, with the potential to accelerate the discovery of novel drugs SAN FRANCISCO, April 28, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today presented data that demonstrate the potential of its DEL Foundation Model to enable the rapid in silico identifi
Nurix's lead BTK degrader, bexobrutideg, demonstrates exceptional efficiency, with a single molecule degrading approximately 10,000 copies of BTK per hour BRAF degrader demonstrates broad activity across all three BRAF mutation classes Aurora A kinase degraders demonstrate potential to address both enzymatic and scaffolding functions and promote tumor regression in brain and small cell lung cancer models SAN FRANCISCO, April 25, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced multiple preclinical presentatio
Collaboration partner, Gilead Sciences, to begin Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy volunteers in Q2 2025 GS-6791/NX-0479 has potential clinical applications across multiple blockbuster markets in inflammation, in both rheumatology and dermatology, including rheumatoid arthritis and atopic dermatitis Nurix to receive a $5 million milestone payment from Gilead for FDA clearance of the IND, bringing the total amount received under the 2019 collaboration agreement to $135 million Nurix is eligible for an additional $420 million in development, regulatory and commercial milestones associated with the IRAK4 degrader program as well as
SAN FRANCISCO, April 11, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases, today announced that on April 8, 2025, the company granted inducement awards to sixteen new employees. The grants were made pursuant to Nurix's 2024 Equity Inducement Plan as an inducement material to the employees' acceptance of employment with Nurix and were approved by the Compensation Committee of Nurix's Board of Directors
NX-5948 assigned the nonproprietary name "bexobrutideg"U.S. FDA Orphan Drug Designation granted to bexobrutideg for the treatment of Waldenström macroglobulinemiaAchieved $7M in milestones and a $15M license extension fee from ongoing collaboration with SanofiEnhanced oversight and leadership team with the appointments of Roy D. Baynes to the Board and John Northcott as chief commercial officerWell capitalized with cash and marketable securities of $549.7 million SAN FRANCISCO, April 08, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medi
The undisclosed target is a central regulator of inflammation that is distinct from the previously disclosed STAT6 program Nurix DEL-AI drug discovery engine generated a drug discovery program to this previously undruggable target Nurix received a $15 million license extension fee from Sanofi under its 2019 collaboration agreement, bringing the total amount received by Nurix to date to $105 million Nurix is eligible for an additional $465 million in development, regulatory and commercial milestones for this program as well as potential future royalties and retains an option to co-develop and co-promote in the United States with the parties splitting U.S. profits and losses SAN FRANCISCO
SAN FRANCISCO, March 25, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that company scientists will present preclinical data from its proprietary DEL-AI platform and several degrader programs in two oral presentations and two poster presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting, which will be held from April 25-30, 2025, in Chicago, IL. Oral Presentation Details: Title: DEL-AI: Proteome-wide in silico screening of multi-billion compound libraries using machine learnin
Orphan Drug Designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenström Macroglobulinemia First-in-class Bruton's tyrosine kinase (BTK) degrader NX-5948 assigned nonproprietary name "bexobrutideg" in newly named degrader class of drugs SAN FRANCISCO, March 17, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to bexobrutideg (NX-5948) for the treatment of Waldenström macroglobulinem
Leerink Partners initiated coverage of Nurix Therapeutics with a rating of Market Perform and set a new price target of $16.00
BTIG Research initiated coverage of Nurix Therapeutics with a rating of Buy and set a new price target of $35.00
BMO Capital Markets initiated coverage of Nurix Therapeutics with a rating of Outperform and set a new price target of $35.00
UBS initiated coverage of Nurix Therapeutics with a rating of Buy and set a new price target of $35.00
Jefferies initiated coverage of Nurix Therapeutics with a rating of Buy and set a new price target of $41.00
Robert W. Baird resumed coverage of Nurix Therapeutics with a rating of Outperform and set a new price target of $26.00
Truist initiated coverage of Nurix Therapeutics with a rating of Buy and set a new price target of $36.00
Oppenheimer resumed coverage of Nurix Therapeutics with a rating of Outperform and set a new price target of $25.00
Barclays initiated coverage of Nurix Therapeutics with a rating of Overweight and set a new price target of $20.00
Oppenheimer initiated coverage of Nurix Therapeutics with a rating of Outperform and set a new price target of $25.00
Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations Clinical responses in CLL patients were rapid and deepening with longer time on treatment Nurix intends to advance NX-5948 into pivotal trial(s) in 2025 Company will host a webcast conference today, June 16, 2024, at 9:00 a.m. ET (3:00 p.m. CEST) SAN FRANCISCO, June 16, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the presentation of updated clinical d
SAN FRANCISCO, June 10, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that the company will host a webcast and conference call at 9:00 a.m., ET, on Sunday, June 16, 2024, to discuss data from the ongoing Phase 1 clinical trial of NX-5948 that will be presented in an oral session at the European Hematology Association Congress in Madrid, Spain. The oral presentation at EHA2024 will summarize updated data from the ongoing Phase 1a/b study of NX-5948 in heavily pretreated patients with relapsed/refractor
Overall response rate of 70% observed in 10 evaluable heavily pretreated CLL patients Data showcase deepening clinical responses with longer time on therapy in CLL patients including patients with resistance mutations to BTK inhibitors The oral presentation at EHA will include additional data at higher dose levels and longer treatment durations Company will host a webcast conference call on June 16 following the data presentation at EHA (details to follow) SAN FRANCISCO, May 14, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory
Nurix and Seagen to develop a portfolio of Degrader-Antibody Conjugates (DACs): antibodies that deliver a targeted protein degrader payload to selectively kill cancer cells Nurix to receive a $60 million upfront payment, in addition to the potential for approximately $3.4 billion in milestone payments plus future royalties Nurix retains an option for U.S. profit sharing and co-promotion on two products arising from the collaboration Nurix to host a conference call today, September 7 at 8:30 a.m. ET SAN FRANCISCO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to
Robust BTK target degradation achieved in all patients treated to date Greater than 90% degradation of BTK was achieved at the 200 mg dose of NX-2127 These data represent the first proof of mechanism of targeted protein degradation in patients with hematologic malignancies Nurix to host a conference call today at 8:30 a.m. ET SAN FRANCISCO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced initial data demonstrating clinically meaningful degradation of Bruton's tyrosine kinase (BTK) in patients with relapsed or refractory B cell malignancies, including in a chronic lympho
Presentation to include initial pharmacokinetic and BTK degradation data Company to host conference call at 8:30 a.m. ET on Wednesday, October 27, 2021 SAN FRANCISCO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that the Company will present initial pharmacokinetic and pharmacodynamic data from its first-in-human, Phase 1 dose-escalation trial of NX-2127 in adults with relapsed or refractory B-cell malignancies at the 4th Annual Targeted Protein Degradation Summit. The presentation will begin at 11:45 a.m. ET on Wednesday, October 27, 2021, and will be given by Nurix pr
4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
8-K - Nurix Therapeutics, Inc. (0001549595) (Filer)
SCHEDULE 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)
SCHEDULE 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)
SCHEDULE 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)
10-Q - Nurix Therapeutics, Inc. (0001549595) (Filer)
8-K - Nurix Therapeutics, Inc. (0001549595) (Filer)
DEFA14A - Nurix Therapeutics, Inc. (0001549595) (Filer)
DEF 14A - Nurix Therapeutics, Inc. (0001549595) (Filer)
8-K - Nurix Therapeutics, Inc. (0001549595) (Filer)
S-8 - Nurix Therapeutics, Inc. (0001549595) (Filer)
SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)
SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)
SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)
SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)
SC 13G - Nurix Therapeutics, Inc. (0001549595) (Subject)
SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)
SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)
SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)
SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)
SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)
NX-5948 assigned the nonproprietary name "bexobrutideg"U.S. FDA Orphan Drug Designation granted to bexobrutideg for the treatment of Waldenström macroglobulinemiaAchieved $7M in milestones and a $15M license extension fee from ongoing collaboration with SanofiEnhanced oversight and leadership team with the appointments of Roy D. Baynes to the Board and John Northcott as chief commercial officerWell capitalized with cash and marketable securities of $549.7 million SAN FRANCISCO, April 08, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medi
SAN FRANCISCO, March 13, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, announced today the appointment of Roy D. Baynes, MB.Bch., M.Med., Ph.D., to its board of directors. Dr. Baynes, who currently serves as executive vice president and chief medical officer of Eikon Therapeutics, has had a distinguished career in hematology and oncology and over 22 years of clinical leadership experience in pharmaceutical and biotech companies. "Roy has been a trusted advisor to Nurix since 2023, and I am delighted to welcome him to our board
Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66th American Society of Hematology Annual Meeting Received PRIME designation from the European Medicines Agency for NX-5948 in CLL Received Fast Track designation from the U.S. FDA for NX-5948 in Waldenstrom's Macroglobulinemia Announced the appointment of John Northcott as Chief Commercial Officer Well capitalized with cash and marketable securities of $609.6 million SAN FRANCISCO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercial
SAN FRANCISCO, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the appointment of John Northcott as chief commercial officer (CCO). Mr. Northcott has over 20 years of commercial experience, including as CCO for several biotechnology companies building commercial organizations and successfully commercializing the first marketed BTK inhibitor ibrutinib. "We are thrilled to have John join the Nurix team as we prepare to launch our pivotal clinical program for NX-5948 in chronic lymphocytic leukemia
SAN FRANCISCO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the appointment of Anil Kapur to its board of directors, effective October 15, 2024. Mr. Kapur has over 25 years of executive experience in pharmaceutical and biotech companies across both U.S. and international markets. "I am delighted to welcome Anil to the Nurix board as we enter this important stage in the company's development and execute on our plan to advance NX-5948 into pivotal clinical testing in 2025 and prepare for future
SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the appointments of Paula G. O'Connor, M.D., as chief medical officer and Pasit Phiasivongsa, Ph.D., as chief technical officer of Nurix. "I am delighted to announce the promotions of both Paula and Pasit, which recognize their significant and ongoing leadership in advancing our pipeline of novel medicines and particularly in accelerating our NX-5948 program in chronic lymphocytic leukemia and non-Hodgkin's lymphoma," said Arthur T. Sa
Nurix leads targeted protein modulation field with its wholly owned clinical stage programs and two strategic collaborations fueled by its DELigase platform Clinical data updates planned for Nurix's two first-in-class BTK degraders in 2023 Clinical data update planned for Nurix's first-in-class CBL-B inhibitor in 2023 Significant progress made across deep pipeline of preclinical candidates SAN FRANCISCO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today outlined key objectives and anticipated mil
Completed two registered direct offerings in July raising gross proceeds of $95 million Maintained strong financial position with $413.6 million in cash and marketable securities as of August 31, 2022 Expanded leadership team and board of directors with experienced industry leaders Announced multiple presentations at upcoming SITC 2022 annual meeting, including initial PK/PD data for NX-1607 program SAN FRANCISCO, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today reported financial results for the third quarter ended August 31, 2022 and provided a corporate update. "
SAN FRANCISCO, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced the appointment of Edward C. Saltzman to its board of directors. Mr. Saltzman has over 30 years of drug strategic development experience in the biopharmaceutical and biotechnology industries, and currently serves as Head of Biotech Strategy at Lumanity Inc., a global pharmaceutical and biotechnology advisory firm. "I am delighted to welcome Ed to the Nurix board of directors at this important stage in the Company's growth as we advance multiple programs through clinical trials with significant p
SAN FRANCISCO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced that Eric Schlezinger, J.D. has joined the company as chief people officer. Mr. Schlezinger is an industry veteran with extensive experience leading and developing human resources at high-growth private and public biopharma companies. "Eric is a proven leader in building and maintaining exceptional company cultures and has an impressive track record in recruiting and retaining top talent in growing biopharmaceutical companies," said Arthur T. Sands, M.D., Ph.D., president and chief executive office